| Domain | Best-supported finding | Evidence type/strength | Key limitation |
|---|---|---|---|
| Defining cohort | Three affected children were reported in one consanguineous family from eastern Turkey. (pqac-00000000, pqac-00000003) | Human family study; foundational but single-family evidence | No independent human replication cohort was identified. |
| Onset and course | Early development and walking were initially normal; deterioration of gait, vision, and hearing began at approximately 3 years and progressed. One individual lost walking by age 12. (pqac-00000001, pqac-00000020, pqac-00000021) | Direct longitudinal clinical histories from three affected relatives | Retrospective histories; no standardized natural-history assessments. |
| Core phenotype | Progressive complicated hereditary spastic paraplegia with lower-limb-predominant pyramidal dysfunction, weakness, gait loss, cognitive impairment, retinitis pigmentosa or blindness, sensorineural hearing loss or deafness, and demyelinating polyneuropathy. (pqac-00000001, pqac-00000003) | Direct human clinical, ophthalmologic, audiologic, and electrophysiologic observations | Frequencies derived from three related patients cannot establish the full phenotypic spectrum. |
| Neuroimaging and laboratory findings | MRI abnormalities involved dentate nuclei, corticospinal pathways or internal capsules, and subcortical or periventricular white matter, with mild cerebral or cerebellar atrophy and a thin corpus callosum; spinal MRI was normal. Broad metabolic testing was largely unrevealing, although blood lactate was elevated in some descriptions. (pqac-00000001, pqac-00000003, pqac-00000021) | Direct clinical imaging and biochemical evidence | Findings are neither validated biomarkers nor known to be specific to KLC4 disease. |
| Causal variant | A homozygous KLC4 c.853_871del19 deletion in exon 6 creates a premature termination codon at amino acid 277 and is predicted to remove most cargo-binding tetratricopeptide repeats and the entire C-terminal region. (pqac-00000002, pqac-00000023) | WES, Sanger confirmation, cDNA sequencing, conservation, and predicted protein consequence | Transcript accession and standardized HGVS protein notation were not supplied in the retrieved evidence; direct human-cell functional testing was limited. |
| Inheritance and segregation | All three affected individuals were homozygous; the unaffected parents and two siblings were heterozygous, and another unaffected sibling was homozygous wild type, supporting autosomal-recessive inheritance. (pqac-00000000, pqac-00000022) | Strong within-family cosegregation | Penetrance, expressivity, germline-mosaicism risk, and genotype–phenotype relationships cannot be estimated from one pedigree. |
| Population evidence | The deletion was absent from 650 in-house exomes and legacy public controls, including the 1000 Genomes Project and Exome Variant Server. (pqac-00000002) | Supportive rarity evidence available in 2015 | A current ancestry-matched gnomAD frequency was not established in the retrieved sources; carrier frequency is unknown. |
| Zebrafish mechanism | klc4-mutant zebrafish showed impaired stabilization of nascent sensory-axon branches, altered microtubule dynamics, reduced acetylated tubulin, defective Rab5-positive endosomal transport, abnormal peripheral-axon fasciculation, touch hypersensitivity, and adult anxiety-like behavior. (pqac-00000010, pqac-00000012, pqac-00000013, pqac-00000014) | Peer-reviewed in-vivo model using live imaging and behavioral assays; strong evidence for conserved neuronal functions | The model did not show early degeneration or directly test the human deletion; behavioral findings must not be treated as human phenotypes. |
| Cellular mechanism | KLC4 participates in a CLN6–CRMP2–KLC4 complex associated with anterograde ER-derived-vesicle trafficking in cortical neurites; pathway perturbation correlates with impaired neurite growth and arborization. (pqac-00000016, pqac-00000018) | Biochemical and primary mouse-neuron evidence; mechanistically supportive | Experiments primarily manipulated CLN6 rather than KLC4, making direct applicability to KLC4-associated disease inferential. |
| Diagnostics | Molecular confirmation can use exome or genome sequencing or an appropriate neurodegeneration or HSP panel, followed by variant confirmation, segregation analysis, and careful interpretation. MRI, audiology, ophthalmology, nerve-conduction studies, and metabolic testing characterize disease and exclude mimics. (pqac-00000003, pqac-00000020, pqac-00000022) | Approach supported by the defining family’s diagnostic workflow | No validated KLC4-specific diagnostic criteria, biochemical assay, or biomarker exists. |
| Treatment and trials | No KLC4-specific disease-modifying therapy or relevant clinical trial was identified; management is necessarily supportive and phenotype-directed. | Negative targeted trial search and absence of treatment evidence in the defining report | No response rates, adverse-event data, treatment algorithm, or evidence that experimental CRMP2 modulation benefits KLC4 disease. |
| Epidemiology | Only three related affected individuals constitute the established human evidence base; prevalence, incidence, carrier frequency, geographic distribution, and sex ratio are unknown. (pqac-00000000, pqac-00000006) | Ultra-rare single-family ascertainment | The case count is too small for population estimates or robust phenotype frequencies. |
| Terminology and identifiers | The primary publication names the condition recessive KLC4-associated hereditary spastic paraplegia; “KLC4-related early-childhood-onset neurodegeneration” is a descriptive knowledge-base label rather than a verified standardized disease name. (pqac-00000004, pqac-00000006) | Terminology grounded in the primary report and later mechanistic literature | No disease-specific MONDO, OMIM phenotype, Orphanet, MeSH, or dedicated ICD identifier was verified; identifiers must not be inferred from the gene association alone. |


*Table: Compact appraisal of the human, genetic, mechanistic, diagnostic, and epidemiologic evidence for KLC4-related early-childhood-onset neurodegeneration. It emphasizes that the disease definition rests on one three-patient family and separates direct observations from model-based inference.*